The global joint pain injections market size accounted for USD 5.66 billion in 2024, grew to USD 6.03 billion in 2025 and is projected to surpass around USD 10.73 billion by 2034, representing a healthy CAGR of 6.60% between 2024 and 2034.
Chapter 1. Introduction
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
Chapter 2. Research Methodology
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
Chapter 3. Executive Summary
3.1. Market Snapshot
Chapter 4. Market Variables and Scope
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
Chapter 5. COVID 19 Impact on Joint Pain Injections Market
5.1. COVID-19 Landscape: Joint Pain Injections Industry Impact
5.2. COVID 19 - Impact Assessment for the Industry
5.3. COVID 19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
Chapter 6. Market Dynamics Analysis and Trends
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
Chapter 7. Competitive Landscape
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
Chapter 8. Global Joint Pain Injections Market, By Product
8.1. Joint Pain Injections Market, by Product Type, 2024-2034
8.1.1. Pre-filled injections
8.1.1.1. Market Revenue and Forecast (2021-2034)
8.1.2. Vials
8.1.2.1. Market Revenue and Forecast (2021-2034)
Chapter 9. Global Joint Pain Injections Market, By Injection
9.1. Joint Pain Injections Market, by Injection, 2024-2034
9.1.1. Corticosteroid Injections
9.1.1.1. Market Revenue and Forecast (2021-2034)
9.1.2. Hyaluronic Acid Injections
9.1.2.1. Market Revenue and Forecast (2021-2034)
9.1.3. Platelet-rich Plasma Injections
9.1.3.1. Market Revenue and Forecast (2021-2034)
9.1.4. Placental tissue matrix (PTM) Injections
9.1.4.1. Market Revenue and Forecast (2021-2034)
Chapter 10. Global Joint Pain Injections Market, By Joint Type
10.1. Joint Pain Injections Market, by Joint Type, 2024-2034
10.1.1. Knee and Ankle
10.1.1.1. Market Revenue and Forecast (2021-2034)
10.1.2. Hip
10.1.2.1. Market Revenue and Forecast (2021-2034)
10.1.3. Shoulder and Elbow
10.1.3.1. Market Revenue and Forecast (2021-2034)
10.1.4. Spinal Joints
10.1.4.1. Market Revenue and Forecast (2021-2034)
10.1.5. Others
10.1.5.1. Market Revenue and Forecast (2021-2034)
Chapter 11. Global Joint Pain Injections Market, By Distribution Type
11.1. Joint Pain Injections Market, by Distribution Type, 2024-2034
11.1.1. Hospital Pharmacies
11.1.1.1. Market Revenue and Forecast (2021-2034)
11.1.2. Retail Pharmacies
11.1.2.1. Market Revenue and Forecast (2021-2034)
11.1.3. Online Pharmacies
11.1.3.1. Market Revenue and Forecast (2021-2034)
Chapter 12. Global Joint Pain Injections Market, Regional Estimates and Trend Forecast
12.1. North America
12.1.1. Market Revenue and Forecast, by Product (2021-2034)
12.1.2. Market Revenue and Forecast, by Injection (2021-2034)
12.1.3. Market Revenue and Forecast, by Joint Type (2021-2034)
12.1.4. Market Revenue and Forecast, by Distribution Type (2021-2034)
12.1.5. U.S.
12.1.5.1. Market Revenue and Forecast, by Product (2021-2034)
12.1.5.2. Market Revenue and Forecast, by Injection (2021-2034)
12.1.5.3. Market Revenue and Forecast, by Joint Type (2021-2034)
12.1.5.4. Market Revenue and Forecast, by Distribution Type (2021-2034)
12.1.6. Rest of North America
12.1.6.1. Market Revenue and Forecast, by Product (2021-2034)
12.1.6.2. Market Revenue and Forecast, by Injection (2021-2034)
12.1.6.3. Market Revenue and Forecast, by Joint Type (2021-2034)
12.1.6.4. Market Revenue and Forecast, by Distribution Type (2021-2034)
12.2. Europe
12.2.1. Market Revenue and Forecast, by Product (2021-2034)
12.2.2. Market Revenue and Forecast, by Injection (2021-2034)
12.2.3. Market Revenue and Forecast, by Joint Type (2021-2034)
12.2.4. Market Revenue and Forecast, by Distribution Type (2021-2034)
12.2.5. UK
12.2.5.1. Market Revenue and Forecast, by Product (2021-2034)
12.2.5.2. Market Revenue and Forecast, by Injection (2021-2034)
12.2.5.3. Market Revenue and Forecast, by Joint Type (2021-2034)
12.2.5.4. Market Revenue and Forecast, by Distribution Type (2021-2034)
12.2.6. Germany
12.2.6.1. Market Revenue and Forecast, by Product (2021-2034)
12.2.6.2. Market Revenue and Forecast, by Injection (2021-2034)
12.2.6.3. Market Revenue and Forecast, by Joint Type (2021-2034)
12.2.6.4. Market Revenue and Forecast, by Distribution Type (2021-2034)
12.2.7. France
12.2.7.1. Market Revenue and Forecast, by Product (2021-2034)
12.2.7.2. Market Revenue and Forecast, by Injection (2021-2034)
12.2.7.3. Market Revenue and Forecast, by Joint Type (2021-2034)
12.2.7.4. Market Revenue and Forecast, by Distribution Type (2021-2034)
12.2.8. Rest of Europe
12.2.8.1. Market Revenue and Forecast, by Product (2021-2034)
12.2.8.2. Market Revenue and Forecast, by Injection (2021-2034)
12.2.8.3. Market Revenue and Forecast, by Joint Type (2021-2034)
12.2.8.4. Market Revenue and Forecast, by Distribution Type (2021-2034)
12.3. APAC
12.3.1. Market Revenue and Forecast, by Product (2021-2034)
12.3.2. Market Revenue and Forecast, by Injection (2021-2034)
12.3.3. Market Revenue and Forecast, by Joint Type (2021-2034)
12.3.4. Market Revenue and Forecast, by Distribution Type (2021-2034)
12.3.5. India
12.3.5.1. Market Revenue and Forecast, by Product (2021-2034)
12.3.5.2. Market Revenue and Forecast, by Injection (2021-2034)
12.3.5.3. Market Revenue and Forecast, by Joint Type (2021-2034)
12.3.5.4. Market Revenue and Forecast, by Distribution Type (2021-2034)
12.3.6. China
12.3.6.1. Market Revenue and Forecast, by Product (2021-2034)
12.3.6.2. Market Revenue and Forecast, by Injection (2021-2034)
12.3.6.3. Market Revenue and Forecast, by Joint Type (2021-2034)
12.3.6.4. Market Revenue and Forecast, by Distribution Type (2021-2034)
12.3.7. Japan
12.3.7.1. Market Revenue and Forecast, by Product (2021-2034)
12.3.7.2. Market Revenue and Forecast, by Injection (2021-2034)
12.3.7.3. Market Revenue and Forecast, by Joint Type (2021-2034)
12.3.7.4. Market Revenue and Forecast, by Distribution Type (2021-2034)
12.3.8. Rest of APAC
12.3.8.1. Market Revenue and Forecast, by Product (2021-2034)
12.3.8.2. Market Revenue and Forecast, by Injection (2021-2034)
12.3.8.3. Market Revenue and Forecast, by Joint Type (2021-2034)
12.3.8.4. Market Revenue and Forecast, by Distribution Type (2021-2034)
12.4. MEA
12.4.1. Market Revenue and Forecast, by Product (2021-2034)
12.4.2. Market Revenue and Forecast, by Injection (2021-2034)
12.4.3. Market Revenue and Forecast, by Joint Type (2021-2034)
12.4.4. Market Revenue and Forecast, by Distribution Type (2021-2034)
12.4.5. GCC
12.4.5.1. Market Revenue and Forecast, by Product (2021-2034)
12.4.5.2. Market Revenue and Forecast, by Injection (2021-2034)
12.4.5.3. Market Revenue and Forecast, by Joint Type (2021-2034)
12.4.5.4. Market Revenue and Forecast, by Distribution Type (2021-2034)
12.4.6. North Africa
12.4.6.1. Market Revenue and Forecast, by Product (2021-2034)
12.4.6.2. Market Revenue and Forecast, by Injection (2021-2034)
12.4.6.3. Market Revenue and Forecast, by Joint Type (2021-2034)
12.4.6.4. Market Revenue and Forecast, by Distribution Type (2021-2034)
12.4.7. South Africa
12.4.7.1. Market Revenue and Forecast, by Product (2021-2034)
12.4.7.2. Market Revenue and Forecast, by Injection (2021-2034)
12.4.7.3. Market Revenue and Forecast, by Joint Type (2021-2034)
12.4.7.4. Market Revenue and Forecast, by Distribution Type (2021-2034)
12.4.8. Rest of MEA
12.4.8.1. Market Revenue and Forecast, by Product (2021-2034)
12.4.8.2. Market Revenue and Forecast, by Injection (2021-2034)
12.4.8.3. Market Revenue and Forecast, by Joint Type (2021-2034)
12.4.8.4. Market Revenue and Forecast, by Distribution Type (2021-2034)
12.5. Latin America
12.5.1. Market Revenue and Forecast, by Product (2021-2034)
12.5.2. Market Revenue and Forecast, by Injection (2021-2034)
12.5.3. Market Revenue and Forecast, by Joint Type (2021-2034)
12.5.4. Market Revenue and Forecast, by Distribution Type (2021-2034)
12.5.5. Brazil
12.5.5.1. Market Revenue and Forecast, by Product (2021-2034)
12.5.5.2. Market Revenue and Forecast, by Injection (2021-2034)
12.5.5.3. Market Revenue and Forecast, by Joint Type (2021-2034)
12.5.5.4. Market Revenue and Forecast, by Distribution Type (2021-2034)
12.5.6. Rest of LATAM
12.5.6.1. Market Revenue and Forecast, by Product (2021-2034)
12.5.6.2. Market Revenue and Forecast, by Injection (2021-2034)
12.5.6.3. Market Revenue and Forecast, by Joint Type (2021-2034)
12.5.6.4. Market Revenue and Forecast, by Distribution Type (2021-2034)
Chapter 13. Company Profiles
13.1. Online Pharmacies
13.1.1. Company Overview
13.1.2. Product Offerings
13.1.3. Financial Performance
13.1.4. Recent Initiatives
13.2. Bioventus
13.2.1. Company Overview
13.2.2. Product Offerings
13.2.3. Financial Performance
13.2.4. Recent Initiatives
13.3. Ferring Pharmaceuticals Inc.
13.3.1. Company Overview
13.3.2. Product Offerings
13.3.3. Financial Performance
13.3.4. Recent Initiatives
13.4. Sanofi
13.4.1. Company Overview
13.4.2. Product Offerings
13.4.3. Financial Performance
13.4.4. Recent Initiatives
13.5. Zimmer Biomet Holdings Inc.
13.5.1. Company Overview
13.5.2. Product Offerings
13.5.3. Financial Performance
13.5.4. Recent Initiatives
13.6. Allergen Plc.
13.6.1. Company Overview
13.6.2. Product Offerings
13.6.3. Financial Performance
13.6.4. Recent Initiatives
13.7. Pfizer Inc.
13.7.1. Company Overview
13.7.2. Product Offerings
13.7.3. Financial Performance
13.7.4. Recent Initiatives
13.8. Chugai Pharmaceutical Co. Ltd
13.8.1. Company Overview
13.8.2. Product Offerings
13.8.3. Financial Performance
13.8.4. Recent Initiatives
13.9. SEIKAGAKU Corporation
13.9.1. Company Overview
13.9.2. Product Offerings
13.9.3. Financial Performance
13.9.4. Recent Initiatives
13.10. Ferring B.V.
13.10.1. Company Overview
13.10.2. Product Offerings
13.10.3. Financial Performance
13.10.4. Recent Initiatives
Chapter 14. Research Methodology
14.1. Primary Research
14.2. Secondary Research
14.3. Assumptions
Chapter 15. Appendix
15.1. About Us
15.2. Glossary of Terms
No cookie-cutter, only authentic analysis – take the 1st step to become a Precedence Research client
Report Description
Get a Sample